New siRNA drug aims to tame kidney disease

NCT ID NCT06989359

Recruiting now Disease control Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 study is testing a new drug called ADX-038 in 45 adults with complement-mediated kidney diseases, such as IgA nephropathy and C3G. The drug is an siRNA that targets the complement system, which is overactive in these conditions. Researchers are checking if it is safe and can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ADX-038 (siRNA drug)

What this could lead to

If successful, this could lead to a new treatment option that helps control complement-mediated kidney diseases, potentially slowing disease progression and reducing symptoms.

What could go wrong

This is an early Phase 2 trial with only 45 participants, so results may not apply to everyone. The drug may not work as hoped or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

C3 glomerulonephritis complement 3 glomerulopathy IgA glomerulonephritis IgA nephropathy, susceptibility to, 1 immunoglobulin-mediated membranoproliferative glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C3G COMPLEMENT-MEDIATED KIDNEY DISEASE IC-MPGN IGA NEPHROPATHY (IGAN) IGAN

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ADARx Clinical Site
RECRUITING

Doral, Florida, 33122, United States
ADARx Clinical Site
RECRUITING

Miami, Florida, 33127, United States
ADARx Clinical Site
RECRUITING

Pembroke Pines, Florida, 33029, United States
ADARx Clinical Site
RECRUITING

Iowa City, Iowa, 52242, United States
ADARx Clinical Site
RECRUITING

Shreveport, Louisiana, 71101, United States
ADARx Clinical Site
RECRUITING

Shelby, Michigan, 48315, United States
ADARx Clinical Site
RECRUITING

Great Neck, New York, 11021, United States
ADARx Clinical Site
RECRUITING

Columbus, Ohio, 43210, United States
ADARx Clinical Site
RECRUITING

Dakota Dunes, South Dakota, 57049, United States
ADARx Clinical Site
RECRUITING

Dallas, Texas, 75230, United States
ADARx Clinical Site
RECRUITING

Houston, Texas, 77027, United States
ADARx Clinical Site
RECRUITING

Liverpool, New South Wales, 2170, Australia
ADARx Clinical Site
RECRUITING

Wollongong, New South Wales, 2500, Australia
ADARx Clinical Site
RECRUITING

Sydney, NSW 2139, Australia
ADARx Clinical Site
RECRUITING

Woolloongabba, QLD 4102, Australia
ADARx Clinical Site
RECRUITING

Hong Kong, 2500, Hong Kong
ADARx Clinical Site
RECRUITING

Shatin, Hong Kong
ADARx Clinical Site
RECRUITING

Wŏnju, Gangwon-do, 26426, South Korea
ADARx Clinical Site
RECRUITING

Cheonan, 31151, South Korea
ADARx Clinical Site
RECRUITING

Daegu, 42601, South Korea
ADARx Clinical Site
RECRUITING

Gyeonggi-do, 05278, South Korea
ADARx Clinical Site
RECRUITING

Seoul, 02841, South Korea
ADARx Clinical Site
RECRUITING

Seoul, 03080, South Korea
ADARx Clinical Site
RECRUITING

Seoul, 03722, South Korea
ADARx Clinical Site
RECRUITING

Seoul, 05278, South Korea
ADARx Clinical Site
RECRUITING

Barcelona, 08035, Spain
ADARx Clinical Site
RECRUITING

Madrid, 28041, Spain
ADARx Clinical Site
RECRUITING

Seville, 41009, Spain
ADARx Clinical Site
RECRUITING

Newcastle upon Tyne, UK, NE7 7DN, United Kingdom